Cancer Pancreas, Head and Neck Cancer, Pancreatic Cancer
Conditions
Keywords
[Ga68]MTP220, Positron Emission Tomography Computed Tomography, PET CT Scan
Brief summary
The goal of this research study is to develop a diagnostic tool to help with detection and diagnosis of head and neck cancer (HNC) and pancreatic cancer (PaC). This tool is called a targeted PET tracer, or more specifically a drug named \[Ga-68\]MTP220. The U.S. Food and Drug Administration (FDA) has not yet approved this drug, so researchers are conducting this research study to see if \[Ga-68\]MTP220 is safe and effective at diagnosing pancreatic cancer and head and neck cancer. FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application. Participants will receive a single injection of \[Ga-68\]MTP220 followed by PET/CT imaging at three points after they received the drug. These study procedures will take about 2.5 hours. Participants will also receive a follow-up phone call the day after receiving the drug to talk about any side effects they experienced.
Detailed description
For HNC, the overall 5-year survival rate of HNSCCs remains ∼40-50%. PaCa is the 3rd leading cause of cancer mortality in the US with its incidence expected to double by 2030. The poor survival of HNC and PaCa patients is partly due to the delayed diagnosis. Thus, early detection and diagnosis is pivotal to improve the survival. Currently, there is still an unmet clinical need for novel diagnostic technologies for early accurate detection and diagnosis of HNC and PaCa. In this exploratory first in human phase 0 trial, researchers are testing the use of a \[Ga-68\]MTP220 as a targeted PET tracer to explore the biodistribution, dosimetry, efficacy and safety in pancreatic and head and neck cancer patients.
Interventions
DRUG[Ga-68]MTP220 PET/CT Scan
Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.
Sponsors
Qiubai Li
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants older than 18 years old * Prior biopsy showing pancreatic or head and neck malignancy * Participants have been newly diagnosed and not yet received definitive therapy (including surgery, radiation therapy, or systemic therapy). * Able and willing to provide written informed consent before any protocol-specific procedures are undertaken * Participants willing and able to undergo a PET/CT
Exclusion criteria
* Participants who do not meet the above mentioned inclusion criteria * Participants with severe hepatic and renal dysfunction (Total bilirubin \> 3 mg/dL, Albumin \< 2.8 g/dL, INR \> 2.3 (or prolonged PT), presence of ascites or hepatic encephalopathy (Grade III-IV) End-Stage Renal Disease (ESRD) or eGFR \< 30 mL/min/1.73m², Serum creatinine \> 4 mg/dL or rapidly rising, Need for dialysis (hemodialysis or peritoneal dialysis), uremic symptoms) * Participants \< 18 years old * Participants who refuse to give or are unable to sign the informed consent * Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks * Participants unable to withstand or undergo PET/CT * Pregnant or breast feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biodistribution of [Ga-68]MTP220 in patients with pancreatic cancer and head and neck cancers, as measured by standardized uptake value (SUV) mean and maximum | Time it takes to do imaging study procedures, about 2.5 hours |
| Radiation dosimetry of [Ga-68]MTP220, as measured by dosimetry calculations performed using site software | Time it takes to do imaging study procedures, about 2.5 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Potential of [Ga-68]MTP220 PET/CT for assessing tumor response to immunotherapy in PaCa and HNC, as measured by radiotracer uptake in tumors as compared to background activity, compared to conventional imaging (when available) | Time it takes to do imaging study procedures, about 2.5 hours | A tumor uptake that is low or approaching background levels-reflected by a low SUVmax is suggestive of a favorable treatment response. In contrast, persistently high uptake may indicate disease progression |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in heart rate | Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes | Changes from baseline for vital signs may be tested for differences from zero by time point using ANOVA or paired t-test |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in respiratory rate | Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes | Changes from baseline for vital signs may be tested for differences from zero by time point using ANOVA or paired t-test |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience adverse events (AEs) | Participants will be asked to report AEs via telephone follow-up no more than 1 day after they undergo study imaging | — |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in electrocardiogram (ECG) | Baseline (10 minutes before dose) and at the following points after the start of they received the dose: 10 and 140 minutes | Changes in ECG will be summarized using descriptive statistics |
| Efficacy of [Ga-68]MTP220 PET/CT imaging in detecting PaCa or HNC, as measured by comparison of tumor vs normal tissue uptake of [Ga-68]MTP220, compared to conventional imaging (when available) | Time it takes to do imaging study procedures, about 2.5 hours | Uptake of \[Ga-68\]MTP-220 will be assessed by comparing lesion uptake to background activity |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in blood oxygen saturation | Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes | Changes from baseline for vital signs may be tested for differences from zero by time point using ANOVA or paired t-test |
| Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in blood pressure | Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes | Changes from baseline for vital signs may be tested for differences from zero by time point using ANOVA or paired t-test |
Countries
United States
Contacts
Primary ContactLauren Hahn
Outcome results
None listed